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Abstract
Streptococcus pneumoniae is a serious worldwide pathogen and the focus of numerous vaccine
development projects. Currently the most widely accepted surrogate marker for evaluating the
efficacy of a given vaccine is to utilize ELISA. Measurement of antibody concentration by ELISA
without reduction in cross-reactive antibodies causes an overestimation of antibody concentration
and therefore protection, this is most notable in the aged, an at risk group for this infection. We
compared the immune response to the pneumococcal polysaccharides (PPS) 4 and 14 of 20 young
to 20 elderly adults. Pre-and post-vaccination IgG antibody concentrations and antibody avidity
against PPS4 and PPS14 were measured using two different enzyme-linked immunosorbant assay
(ELISA) absorption protocols. All sera were pre-absorbed with either cell-wall polysaccharide
(CPS), or CPS and serotype 22F polysaccharide.
Pre- and post-vaccination IgG antibody concentrations for serotype 4, but not 14, were significantly
lowered with the additional absorption with serotype 22F polysaccharide in both age groups.
Young and elderly demonstrated a significant increase from pre- to post-immunization antibody
concentration, using either absorption method; and opsonophagocytic antibody titers in response
to both PPS4 and PPS14. The correlation coefficients between ELISA and opsonophagocytic assays
were improved by additional absorption with serotype 22F in response to serotype 4, but not
serotype 14 in all age groups. Opsonophagocytic antibody titers in a sub-group of elderly (>77 years
of age) were significantly lower than the opsonophagocytic antibody concentrations in young
adults.
These results suggest the importance of eliminating cross-reactive antibodies from ELISA
measurements by absorption of serum and an age-related impairment in the antibody response to
pneumococcal polysaccharides.
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Streptococcus pneumoniae is a major human pathogen
responsible for serious infections in all age groups world-
wide. Pneumococcal infections are estimated to cause
around 40,000 deaths per year [1], and are a leading
causes of death in the United States [2]. The highest inci-
dence of pneumococcal infections occurs at the extremes
of age, in the very young and in the elderly. The mortality
rate of invasive pneumoccoal disease increases with age
and is estimated to be 20% in those 65 years of age and
40% in those 85 years of age or older. Moreover, S. pneu-
moniae, is the most common cause of community
acquired pneumonia among the elderly [3] and the fifth
leading cause of death in those 65 years and older [4,5].
Pneumococcal capsular polysaccharide (PPS) is a major
virulence factor of S. pneumoniae and reduces phagocyto-
sis in the host [6,7]. The currently licensed pneumococcal
vaccine consists of 23 purified PPS serotypes, which
account for 76–90% of IPD causing strains [8,9]. The cap-
sular PPS vaccine is based on the observation that anti-
bodies against the capsule protect against disease by
enhancing complement dependent phagocytosis [6].
Pneumococcal vaccination is recommended for all per-
sons 65 years and older in the United States, however, effi-
cacy studies indicate decreased protection among this
target population despite protective levels of anti-pneu-
mococcal antibodies [10,11]. The underlying causes of the
reduced vaccine efficacy merit investigation.
Reports of the diminished vaccine efficacy in the elderly
may reflect either poor functionality of vaccine induced
anti-PPS specific antibodies or inconsistent antibody
measurements. Protection is measured by in vitro analysis
of opsonophagocytosis by anti-polysaccharide antibodies
and serves as a surrogate marker of clinical protection
[12]. However, the opsonophagocytic assay is labor inten-
sive and difficult to perform and therefore impractical,
when analyzing large numbers of samples. Therefore,
alternate methods for measuring pneumococcal antibody
concentrations, namely ELISA, have been developed.
More practical than opsonophagocytic assays, the
polysaccharide-specific antibody concentrations meas-
ured by ELISA do not necessarily correlate with functional
antibody activity. The development of an ELISA method
that accurately reflects functional antibody activity and
can serve as a surrogate marker of protection is of utmost
importance.
The enzyme-linked immunosorbant assay (ELISA)
method used to measure PPS-specific antibody concentra-
tions has changed considerably over the past 20 years. The
presence of cell wall polysaccharide (CPS), covalently
linked to the type-specific polysaccharide, led to poor cor-
relations between antibody concentration and pneumo-
coccal vaccine efficacy [13,14]. The realization that the
measurement of anti-CPS antibodies caused an overesti-
mation of anti-PPS antibody concentration led to a mod-
ification of the pneumococcal ELISA procedure to include
an absorption step, removing cell wall polysaccharide
directed antibodies [13,15]. Recent studies have demon-
strated that the additional absorption of sera with CPS
and serotype 22F PPS significantly increases the correla-
tion between antibody concentration and opsonophago-
cytic activity compared to CPS absorption alone [16].
Previously, a study performed in elderly adults demon-
strated a significant decrease in opsonophagocytic activity
in response to PPS4 despite normal antibody concentra-
tions [17]. The decrease in functional antibody activity
increased with age and was serotype specific. The immune
response to PPS14, as determined by antibody concentra-
tion and opsonophagocytic antibody activity, was well
conserved in the elderly. However, in this study, an older
version of the PPS-ELISA relying solely on CPS absorption
was used to determine antibody concentration. Therefore,
non-specific cross-reactive antibodies may have been
responsible for the discrepancy between antibody concen-
tration and opsonophagocytic activity to PPS4.
The aim of this study was to re-assess the response of eld-
erly (>65 years old) adults to PPS4 and PPS14 employing
the recently modified PPS-specific ELISA. We have under-
taken the present study to further elucidate the nature of
the elderly immune response to PPS in an effort to define
correlates of protection in the ageing population. Should
the elderly response contain a significant proportion of
low avidity, cross-reactive antibodies as previously sug-
gested [17] one would expect that absorption with PPS
22F would have a greater impact on antibody concentra-
tion and avidity measurements in the elderly than young.
Results
All volunteers were considered immune competent based
on health history, complete blood cell counts, total
immunoglobulin levels and quantitative B-cell and T-cell
subset studies. There was no quantitative difference in
number of B-cells or CD4+ and CD8+ T cells in the young
versus elderly participants (Table 1).
Anti-pneumococcal Antibody Concentrations
Anti-PPS4 and PPS14 antibody concentrations were deter-
mined by the two ELISA methods, absorption with either
CPS or CPS + PPS22F. Geometric mean IgG antibody con-
centrations (µg/ml) and 95% CI are shown in Table 2.
In response to PPS4 a significant increase in pre-to post-
immunization antibody concentration was detected by
both ELISA methods in both age groups (p range 0.003 –
0.005). When both ELISA methods were compared aPage 2 of 9
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observed following CPS + PPS22F absorption in young
volunteers' pre-and post-immune sera (18.6 %, p = 0.033
and 14%, p = 0.036 respectively) and elderly volunteers'
pre-immune (28.4, p = 0.008) but not post-immune sera
(11.4%, p = 0.142). There was no significant difference in
the antibody levels detected between young and elderly
volunteers in pre-or post-immunization sera using either
absorption method, although young pre-immune sera
tended to demonstrate lower geometric mean concentra-
tions (GMC). However, more young than elderly demon-
strated a two-fold or greater increase pre-post
immunization (83% compared to 50%).
In response to PPS14, a similar significant increase in pre-
to post-immunization antibody concentration was
detected in all groups (p range 0.001–0.006). When both
ELISA methods were compared there was no significant
difference in IgG concentrations in young sera using either
method. However, in the elderly the addition of PPS22F
absorption significantly reduced the IgG concentration
detected in post-(10.6%, p = 0.013) but not pre-immuni-
zation sera (0.8%, p = 0.367). There was a tendency
towards lower antibody concentrations in the pre-
immune sera of the young in comparison to the elderly,
although this was not significant. The post-immune anti-
PPS14 antibody concentrations were also not significantly
different between young and elderly groups. However,
more young than elderly demonstrated a two fold or
greater increase in serum IgG concentrations, 90% and
55% respectively.
Our study was designed to compare the immune reaction
to PPS in young adults (18 – 30 years old) to elderly (>65
years of age). However, several studies [17,18] indicate
that the oldest elderly (>77 years of age) demonstrate a
significant decrease in the immune response to PPS. We
thus analyzed the results obtained for a subgroup of eld-
erly >77 years old within our study population. In this
small subgroup (n = 6) additional absorption with
PPS22F resulted in a substantial but not significant
decrease in measured antibody concentration of 28% in
Table 1: Measurement of T and B cell parameters in young and elderly volunteers.
CD4+ T cells GMN 
(95% CI)
CD8+ T cells GMN 
(95% CI)
B cells GMN 
(95% CI)
Total IgG GMC 
(95% CI)
Normal Range 430 – 1185 180 – 865 25 – 285 591–1540
Young 879 (758–1000) 573 (487–659) 235 (156–314) 838 (757–919)
Elderly 817 (692–942) 396 (303–489) 164 (93–235) 993 (956–1030)
GMC = geometric mean concentration (ug/ml), GMN geometric mean number per ml. There was no significant difference (P>0.05) between young 
and elderly for all values.
Table 2: Specific anti-PPS IgG antibody levels in young and elderly.
Pre-immune serum GMC (95% CI)
CPS CPS + 22F P value
PPS4 Young 1.5 (0.59–2.41) 1.22 (0.77–1.66) 0.033
Elderly 1.94 (0.85–3.03) 1.39 (0.97–1.81) 0.008
PPS14 Young 3.86 (2.54–5.18) 4.02 (2.10–5.94) 0.370
Elderly 4.77 (1.61–7.93) 4.73 (2.42–7.04) 0.367
Post-immune serum GMC (95% CI)
CPS CPS + 22F P value
PPS4 Young 4.03 (1.68–6.38) 3.45 (1.62–5.28) 0.036
Elderly 3.95 (0.73–7.17) 3.50 (1.01–5.99) 0.142
PPS14 Young 18.41 (7.24–29.58) 18.43 (8.46–28.40) 0.708
Elderly 11.43 (4.44–18.42) 10.22 (3.35–17.09) 0.013
Geometric mean concentration (GMC, µg/ml) of specific anti-PPS IgG antibody in pre-and post-immunization serum from young and elderly 
volunteers by two ELISA methods. CPS – serum adsorbed with CPS prior to ELISA. CPS+22F – serum absorbed with PPS22F and CPS prior to 
ELISA. P values shown in bold indicate significant difference between absorption methods by two tailed paired Student's T-test.Page 3 of 9
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ison to young adults. A significant increase from pre-to
post-immunization antibody concentration in response
to PPS4 was only found when sera were absorbed with
CPS (p = 0.05) but not when sera were absorbed with CPS
+ PPS22F (p = 0.069). There was no significant increase in
pre-to post-immunization antibody levels against PPS14
for either method (p = 0.094 for both). Although, the
post-immunization anti-PPS14 IgG GMC of the young
adult group was not significantly different from the eld-
erly, it was significantly higher than the sub-group of eld-
erly >77 years old using both absorption methods (p =
0.035 and p = 0.022). There was a reduction in the pro-
portion of this subgroup that demonstrated a two-fold or
greater increase in IgG levels pre-post immunization, in
response to both PPS4 (29%) and PPS14 (43%) than
either all elderly (50% and 55% respectively) and young
(83% and 90% respectively).
Immunoglobulin Isotype and Subclass
The predominant immunoglobulin isotype expressed in
response to both PPS4 and PPS14 consisted of IgG.
Despite a significant increase from pre-to post-immuniza-
tion, the GMC of the PPS-specific IgM and IgA antibody
concentrations in response to both PPS did not exceed
one microgram per millilitre in young or elderly. Moreo-
ver, there was no significant difference in either IgM or IgA
antibody concentrations in young versus elderly. Addi-
tional absorption with PPS22F reduced both IgM and IgA
concentrations in young and elderly alike, but not signifi-
cantly so.
As shown in Table 3, the IgG response to PPS4 and PPS14
was dominated by the IgG2 subclass in young and elderly
adults as previously reported [19,20]. In response to PPS4,
67.5 to 80.5 % of the total IgG antibody concentration
measured consisted of IgG2, with no significant difference
between young and elderly or pre-to post-immunization.
Similarly, of the pre-and post-immune total PPS14-spe-
cific IgG antibody, 63.7 to 73% of the response consisted
of IgG2 with no significant difference between age groups.
PPS-specific IgG1 antibodies were also readily detectable
and increased significantly post-vaccination in both age
groups. Overall, IgG1 antibodies represented 9.5 to 11.2%
of total IgG antibodies in response to PPS4 and 18.7 to
25.4% of total IgG antibodies measured in response to
PPS14. There was no significant difference detected in
either IgG1 antibody concentration or percent usage
between young and elderly.
Additional absorption of sera with PPS22F did not affect
either pre-or post-immunization IgG1 PPS4 or PPS14
concentrations in either age group or the IgG2 response to
PPS14. However, in response to PPS4, absorption with
PPS22F significantly reduced pre-and post-immunization
IgG2 concentrations in both young and elderly (17 to
27% with p = 0.019 to 0.025).
Opsonophagocytic Activity
Opsonophagocytic activity was measured in pre-and post-
immunization sera against pneumococcal serotypes 4 and
14. Geometric mean titers (GMT) and ranges are shown in
Table 4.
In response to serotypes 4 and 14 both young and elderly
demonstrated a significant increase pre-to post-immuni-
zation (p range 0.0003–0.001). There was no significant
difference between the opsonophagocytic titers in young
and elderly for either polysaccharide (p range 0.203–







PPS4 Young 0.13 (0.06) 0.35 (0.18) 0.001
Elderly 0.14 (0.09) 0.33 (0.38) 0.051
PPS14 Young 0.87 (0.13) 3.59 (0.33) 0.001
Elderly 0.93 (0.44) 1.19 (0.95) 0.015
IgG2
PPS4 Young 1.03 (0.37–1.69) 5.14 (0.64–9.64) 0.010
Elderly 0.83 (0.04–1.62) 1.96 (0.98–2.94) 0.005
PPS14 Young 2.18 (1.86–2.50) 12.33 (4.51–20.15) 0.002
Elderly 1.36 (0.62–2.10) 4.78 (2.37–7.19) 0.004
Geometric mean concentration (GMC µg/ml) of anti-PPS antibody in pre-and post-immunization serum from young and elderly volunteers 
measured following absorption with CPS. P values shown in bold indicate significant difference between pre and post immunization by two tailed 
paired students T-testPage 4 of 9
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separately there was a significant increase in
opsonophagocytic activity only in response to serotype 14
(p = 0.04) but not in response to serotype 4 (p = 0.214).
The post immunization titers for the eldest subgroup for
serotype 4 (GMT 35.92) and 14 (90.51) were significantly
lower than in young donors (p = 0.03 and 0.02), all eld-
erly donors (p = 0.01 for both) and the younger group of
elderly (p = 0.002, 0.001).
Antibody Avidity Measurements
Antibody avidity was determined using sodium thiocy-
anate (NaSCN) in both ELISA methods as described. Geo-
metric mean concentrations (GMC, M NaSCN) and
ranges are given in Table 5. The addition of PPS22F to the
assay did not significantly change the avidity measure-
ments, pre-or post-immunization, in young or elderly (p
range 0.053 – 0.715) except in young anti-PPS14 post
immunization sera (p = 0.04). In response to PPS4 there
was no significant difference between young and elderly
in any group analyzed (p range 0.32 – 0.93). In response
to PPS14 a significant difference was detected between
young and elderly pre-immune sera when absorbed with
CPS alone (p = 0.03) and post-immune sera when
absorbed with CPS and PPS22F (p = 0.03).
Anti-PPS4 antibodies demonstrated a significant increase
in avidity pre-to post-vaccination in elderly volunteers by
both methods (p = 0.01, 0.003) but not in the young (p =
0.147, 0.257). Young anti-PPS14 antibodies showed a
significant increase pre-to post-immunization when sera
were absorbed with CPS alone (p = 0.015) but not CPS
and PPS22F (p = 0.061). Avidity of elderly anti-PPS14
antibodies pre-and post-immunization was significantly
different by both methods (p = 0.007, 0.002).
In the oldest subgroup of elderly anti-PPS4, but not anti-
PPS14, antibodies, when absorbed with CPS and 22F
demonstrated a significant increase pre-to post-immuni-
zation (p = 0.03). There was no significant difference
between avidity measurements in this subgroup com-
pared to either young, all elderly or the youngest elderly.






PPS4 Young 10.2 (4.43–15.97) 93.6 (-19.63–206.89) 0.001
Elderly 14.9 (2.74–27.12) 147.0 (-16.63–310.70) 0.001
PPS14 Young 16.7 (-33.03–66.36) 245.8 (82.50–409.05) 0.0004
Elderly 26.9 (-104.78–158.60) 265.03 (115.74–414.32) 0.0003
Geometric mean titer of serotype specific opsonophagocytic activity in pre-and post-immunization serum, from young and elderly volunteers. 
Significance of increase from pre to post-immunization was calculated using two tailed paired students T-test.
Table 5: Avidity of anti-PPS antibodies from young and elderly.
Pre-immune serum GMC (95% CI)
CPS CPS + 22F P value
PPS4 Young 0.19 (0.07–0.32) 0.21 (0.04–0.38) 0.091
Elderly 0.22 (0.13–0.31) 0.22 (0.12–0.31) 0.646
PPS14 Young 0.28 (0.21–0.36) 0.27 (0.19–0.35) 0.711
Elderly 0.43 (0.27–0.59) 0.42 (0.27–0.56) 0.196
Post-immune serum GMC (95% CI)
CPS CPS+22F P value
PPS4 Young 0.35 (0.22–0.49) 0.40 (0.25–0.55) 0.053
Elderly 0.43 (0.23–0.63) 0.46 (0.26–0.65) 0.014
PPS14 Young 0.47 (0.33–0.62) 0.41 (0.29–0.54) 0.618
Elderly 0.68 (0.50–0.85) 0.66 (0.48–0.84) 0.715
Geometric Mean Concentration (GMC, M NaSCN) representing serum avidity by two different ELISA methods. CPS – serum adsorbed with CPS 
prior to ELISA. CPS+22F – serum absorbed with PPS22F and CPS prior to ELISA. P values shown in bold indicate a significant difference between 
absorption methods calculated using paired Student's T-test.Page 5 of 9
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and Antibody Concentrations
Correlation coefficients of association (r values) were
determined between log2 IgG antibody levels and log2
opsonophagocytic titers for PPS4 and PPS14 by absorbing
sera with CPS or CPS and PPS22F (Table 6). In response
to PPS4, the correlation coefficient increased following
CPS+ PPS22F absorption in young adults from an r value
of 0.64 (CPS absorption) to 0.81 (CPS+ PPS22F absorp-
tion). A similar increase from 0.69 with CPS and 0.79
with CPS+PPS22F absorption was noted in the elderly.
The sub-group of elderly >77 years of age showed a corre-
lation coefficient of 0.73 following absorption with CPS
that increased to 0.87 following absorption with CPS and
PPS22F. Thus, all age groups demonstrated a significant
correlation between antibody concentration and
opsonophagocytic antibody response that improved by
additional absorption with CPS and PPS22F.
In addition, all age groups demonstrated a relatively high
correlation between antibody concentration and func-
tional antibody activity in response to PPS14. Additional
absorption with PPS22F did not improve the correlation
coefficients of association between IgG antibody concen-
trations and opsonophagocytic titers for PPS14. All age
groups showed a significant correlation between antibody
concentrations and opsonophagocytic antibody activity
as previously reported in adults [16].
Correlation between Opsonophagocytic Antibody Activity 
and Antibody Avidity
We also determined the correlation coefficients of associ-
ation (r values) between concentration of NaSCN neces-
sary to reduce ELISA optical density by 50% and log2
opsonophagocytic titers for PPS4 and PPS14. In response
to PPS4, all groups showed a relatively poor correlation
between avidity and opsonophagocytic activity (Table 7)
that improved marginally after absorption with CPS and
PPS22F. In the sub-group of elderly >77 years the correla-
tion of association was very poor, however the r value
improved markedly from 0.069 to 0.25 by additional
absorption with PPS22F.
In response to PPS14, the correlation coefficients of asso-
ciation were better than those in response to PPS4 (Table
7). The additional absorption with PPS22F however, did
not significantly affect the correlation coefficients of
association.
Discussion
Recent improvements in the ELISA method used to meas-
ure anti-pneumococcal polysaccharide-specific antibod-
ies, aimed at removing non-specific antibodies, have
resulted in a significant increase in the correlation
between antibody concentration and opsonophagocytic
activity [16]. Although this methodology has been exten-
sively evaluated in healthy adults [16] the effect of addi-
Table 6: Correlation between opsonophagocytic titers and antibody concentration.
CPS CPS + PPS22F P value
PPS4 Young 0.64 0.81 0.28
Elderly 0.69 0.79 0.51
PPS14 Young 0.90 0.88 0.78
Elderly 0.75 0.72 0.85
Correlation coefficients of association (r values) between post-immunization opsonophagocytic titer and antibody concentration following 
absorption with CPS or CPS + 22F in young and elderly volunteers. There was no significant difference between absorption techniques by Fisher's 
Z transformation.
Table 7: Correlation between opsonophagocytic titers and antibody avidity.
CPS CPS + PPS22F P value
PPS4 Young 0.39 0.44 0.86
Elderly 0.52 0.53 0.97
PPS14 Young 0.51 0.49 0.94
Elderly 0.64 0.59 0.81
Correlation coefficients of association (r value) between post-immunization opsonophagocytic antibody titer and antibody avidity following 
absorption with CPS or CPS + 22F in young and elderly volunteers. There was no significant difference between absorption techniques by Fisher's 
Z transformation.Page 6 of 9
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antibody response in elderly adults has not been deter-
mined. The presence of non-serotype specific, poorly
functional antibodies may in fact explain the discrepancy
between measured antibody concentrations and func-
tional antibody activity in the elderly.
The results of the present study indicate that both young
and elderly adults respond to pneumococcal vaccination
with a significant increase in PPS-specific antibody con-
centration, although the fold increase in antibody concen-
tration was lower in elderly. Additional absorption with
PPS22F resulted in a significant reduction in antibody
concentration to PPS4 but did not affect the antibody con-
centration measurements to PPS14. It is likely that PPS14
does not contain cross-reactive antigens or contaminants
as described for other pneumococcal polysaccharides
[16,21,22]. The decrease in measured anti-PPS4 antibody
resulted in an increased correlation between antibody
concentration and functional antibody activity, consistent
with previous studies [16]. Although the decrease in anti-
PPS4 antibody was more pronounced in pre-immune
sera, it was not significantly different between young and
all elderly and did not affect fold-increase in antibody
concentration post-immunization. The results of previous
studies [18,23] however, indicate that an impaired
immune response to PPS is limited to the oldest elderly.
Although small in number (n = 6), separate analysis of
elderly > 77 years of age showed a decrease in significance
of the increase from pre-post when the sera was absorbed
with PPS22F. In addition fewer volunteers in this age
group demonstrated a two fold or greater increase in anti-
body concentration pre-post than either the young or eld-
erly. These results suggest that previous studies may have
shown an overestimation of antibody concentration and
that this may be particularly critical in the oldest elderly
population. The additional absorption with PPS22F thus
revealed a potential impairment in quantitative antibody
response to PPS4 in the oldest age group.
Several studies have demonstrated that reduced or absent
functional antibody activity is directly related to low anti-
body avidity and not necessarily a result of low antibody
concentration [24,25]. Specifically, it has been demon-
strated that post-vaccination sera from elderly with low
opsonophagocytic activity correlate with low IgG anti-
body avidity [23]. Additional absorption with PPS22F,
which serves to remove non-specific antibodies with pre-
sumably low avidity, should in principle result in
increased avidity measurement. In response to PPS4,
absorption of sera with CPS and PPS22F increased anti-
body avidity in young and elderly adults, although this
increase was only significant in the young. However, the
moderate correlation between opsonophagocytic anti-
body titers and antibody avidity in both young and eld-
erly, did not improve significantly following absorption
with PPS22F. These data suggest that high avidity antibod-
ies are not necessarily functional, or conversely,
opsonophagocytic antibodies are not necessarily of high
avidity. In contrast, in response to PPS14, there was a
strong correlation between opsonophagocytic antibody
titers and antibody avidity in all age groups, including eld-
erly > 77. Similarly, Romero-Steiner, et al. [23] found a
significant correlation between serum opsonophagocytic
activity and antibody avidity, particularly in response to
PPS14. In most elderly individuals, specifically those > 77
years of age, low opsonophagocytic antibody activity was
directly related to low antibody avidity.
Opsonophagocytic activity is dependent on both anti-
body avidity and antibody concentrations. In the elderly,
particularly those > 77 years old, lack of correlation
between functional antibody activity and antibody avidity
was generally attributable to low antibody concentra-
tions. In contrast, some of the young volunteers with low
opsonophagocytic activity demonstrated moderate to
high antibody concentrations with moderate or high anti-
body avidity. These data suggest that young adults in par-
ticular, may generate high levels of high avidity
antibodies, not directed at opsonophagocytic epitopes.
Based on these data, we propose that at least two different
mechanisms may be responsible for the discrepancy
between antibody concentration and functional antibody
activity, namely, poor antibody avidity and antibodies
directed at non-opsonophagocytic epitopes present on
the pneumococcal polysaccharide.
While overall there was no statistical difference between
the response in young and elderly there was a trend
towards a reduced response which increased with age.
Less of the eldest subgroup of elderly responded to the
vaccine with a two fold or greater concentration of anti-
body than either all elderly or young. Immunosenescence
is an ongoing process with age; as the patient ages the
immune system continues to decline. Thus, in studies
aimed at detecting the most differences with ageing,
future studies should aim to enroll older elderly, i.e. those
over 75 years of age.
Conclusion
Our study indicates that additional absorption of serum
with PPS22F results in an improved correlation between
measured antibody concentration and functional anti-
body activity in young and elderly adults. The removal of
non-specific antibodies may, however, be of particular
importance in assessing PPS-specific antibody concentra-
tion in elderly and may uncover previously un-noted dif-
ferences in quantitative antibody response.Page 7 of 9
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Human Volunteers/Vaccination
Healthy young adults (<30 years old) and elderly volun-
teers (>65 years old) were asked to participate in this
study. Elderly volunteers were recruited from the commu-
nity as well as from the general internal medicine clinic at
Medical College of Ohio. Young volunteers were recruited
from the student population at MCO. Each individual was
questioned concerning prior pneumococcal vaccination,
medications, previous illness and present health. In addi-
tion, we obtained complete blood count (CBC), compre-
hensive chemistry profile including renal and liver
functions and serum albumin, total B cells, T cell subsets
and total IgG, IgM and IgA levels in all study candidates.
Individuals previously immunized with the pneumococ-
cal vaccine and any individual considered to be immuno-
compromised on basis of medication (chemotherapy,
steroid preparations, immunosuppressive agents includ-
ing anti-TNFa agents), previous/present illness (previous
pneumococcal disease, splenectomy, auto-immune dis-
ease, end-stage renal or liver disease, HIV positivity, organ
transplant or cancer) and those with abnormal CBC,
chemistries, B or T cells or immunoglobulin levels did not
qualify. Informed consent was obtained from all partici-
pants using protocols reviewed and approved by Institu-
tional Review Board of Medical College of Ohio.
Pneumococcal Polysaccharide ELISA
ELISA was used to determine the anti-PPS specific human
antibodies, isotypes and subclasses, in all volunteers
before and 6 weeks after vaccination [23,26]. Comprehen-
sive details regarding this procedure are found in the web
document: http://www.vaccine.uab.edu. US reference
Pneumococcal Antiserum 89SF, courtesy of Dr Carl Frasch
CBER/FDA, was used as a control throughout.
Briefly, Nunc microtiter plates were coated with PPS4 or
PPS14 (ATCC, Rockville, Md.). Human sera were
absorbed with 5 µg/ml of cell wall polysaccharide (CPS)
or with 5 µg/ml of CPS and 10 µg/ml of serotype 22F
polysaccharide (ATCC) and incubated for 30 minutes
[26]. Serial dilutions of absorbed sera were added to the
wells and incubated. Horse-radish peroxidase labeled
anti-human isotype and subclass specific conjugates were
added and reaction developed with σ-phenylenediamine
(Sigma, St. Louis), absorbance was read at 490 nm.
Antibody Avidity ELISA
Avidity of IgG antibodies to PPS4 and PPS14 was deter-
mined by sodium thiocyanate (NaSCN), a chaotropic
agent that interferes with antigen-antibody interaction
[27]. The molarity of NaSCN required to elute 50% of
bound antibody was used as a measure of avidity, the rel-
ative strength of antigen-antibody binding. ELISA was per-
formed as previously described [23]. Microtiter plates
were set up with NaSCN molarity ranges from 4 M to
0.0625 M. Controls consisted of uninhibited serum sam-
ples and blanks. All serum samples were tested in dupli-
cate. Avidity was expressed as the molarity of NaSCN
required to inhibit 50% of binding of uninhibited serum.
Opsonophagocytic Assays
Opsonophagocytic assays were performed as previously
described [23,28] to measure the functional antibodies
against PPS4 and PPS14. Briefly, viable pneumococci were
allowed to pre-opsonize with serially diluted heat-inacti-
vated sera. Newborn rabbit serum (Pel-Freez, Brown Deer,
WI) was added as source of complement (12.5%).
Washed, differentiated cells were added at a 400:1 effec-
tor: target cell ratio. After incubation, to allow phagocyto-
sis to occur, an aliquot was plated and incubated
overnight at 37°C with 5% CO2. The opsonophagocytic
titer was determined as the reciprocal of the dilution with
>50% killing when compared to the control wells without
serum.
Statistics
Geometric mean concentrations of IgG reactive with PPS4
and PPS14 were calculated for each group. Pre-to post-
immunization values were compared using paired Stu-
dent's T test, young and elderly were compared using two
sample, unpaired Student's T test. Correlation coefficients
and p values were calculated using Fisher's Z transforma-
tion using log2 base of opsonophagocytic titers and anti-
body concentrations. P values less than 0.05 were
considered to be significant. Statistical calculations were
performed with use of SPSS software 11.5.1.
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